CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

Rheumatoid Factor and Anti-cyclic Citrullinated Peptide Testing for Arthralgia: Diagnostic Accuracy, Clinical Utility, and Guidelines

Last updated: November 26, 2020
Project Number: RB1529-000
Product Line: Rapid Response
Research Type: Other Diagnostics
Report Type: Summary of Abstracts
Result type: Report

Question

  1. What is the diagnostic accuracy of rheumatoid factor tests for patients presenting with arthralgia but no arthritis on a physical exam?
  2. What is the diagnostic accuracy of anti-cyclic citrullinated peptide tests for patients presenting with arthralgia but no arthritis on physical exam?
  3. What is the clinical utility of rheumatoid factor tests for patients presenting with arthralgia but no arthritis on physical exam?
  4. What is the clinical utility of anti-cyclic citrullinated peptide tests for patients presenting with arthralgia but no arthritis on physical exam?
  5. What are the evidence-based guidelines regarding rheumatoid factor tests or anti-cyclic citrullinated peptide tests for patients presenting with arthralgia but no arthritis on physical exam?

Key Message

One non-randomized study was identified regarding the diagnostic accuracy of rheumatoid factor tests and anti-cyclic citrullinated peptide tests for patients presenting with arthralgia but no arthritis on a physical exam. No relevant literature was identified regarding the clinical utility of rheumatoid factor tests or anti-cyclic citrullinated peptide tests for patients presenting with arthralgia but no arthritis on physical exam. No relevant evidence-based guidelines were identified regarding rheumatoid factor tests or anti-cyclic citrullinated peptide tests for patients presenting with arthralgia but no arthritis on physical exam.